NEM® open label human clinical trials
ESM Technologies’ NEM® (Natural Eggshell Membrane) is a proven ingredient for the joint health market that delivers fast results. Two 30-day open label human clinical trials were conducted to evaluate NEM® (500mg once daily) as a treatment for various joint and connective tissue disorders.
Effect of NEM® on Joint Pain
The results of the studies showed that supplementation with NEM® produced an average 25% reduction in pain (both Study 1 & Study 2) in just 7 days. By the end of the 30-day trial, patients in Study 1 had an average reduction in pain of more than 72% (See graph) and nearly half of these patients reported that they were completely pain-free by the end of the study. Patients in Study 2 experienced more moderate relief with an average 30% reduction in pain at the completion of the trial, however about one-third of them experienced more than 50% reduction in pain. No side effects were reported by study participants in either trial.
Effect of NEM® on Range of Motion
Supplementation with NEM® also produced an average 28% increase in flexibility in just 7 days for patients in Study 1. Flexibility had improved by an average 44% by the end of the study (See graph left) with more than half of the patients experiencing greater than 50% improvement in flexibility by day 30. NEM® not only improved joint flexibility, it also reduced the pain patients experienced while flexing the affected joint in a range of motion (ROM) evaluation. At day 7, patients had 43% less pain while flexing, and by day 30, this had improved to 76% less pain while flexing. Again, no side effects were reported by study participants.
Supplementation with NEM® produced a significant treatment response at:
- 7 days for flexibility (27.8% increase, P = 0.038)
- 30 days for general pain (72.5% reduction, P = 0.007)
- 30 days for flexibility (43.7% increase, P = 0.006)
- 30 days for ROM-associated pain (75.9% reduction, P = 0.021)
Supplementation with NEM® produced a significant treatment response for pain at 7 days for both treatment arms.
(X: 18.4% reduction, P = 0.021, Y: 31.3% reduction, P = 0.014)
There was no clinically meaningful difference between treatment arms at 7 days, so the Y arm crossed over to the X formulation for the remainder of the study.
The significant treatment response continued through 30 days for pain. (30.2% reduction, P = 0.0001)